Ireland-headquartered Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced positive results from a Phase III study of Xywav (calcium, magnesium, potassium, and sodium oxybates).
The oral solution is being tested as a treatment for adults with idiopathic hypersomnia, an often debilitating sleep disorder characterized by chronic excessive daytime sleepiness.
The data are being presented during a plenary session of the 2021 American Academy of Neurology (AAN) annual meeting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze